Two Decades of Sjögren’s Syndrome Biomarker Research Reveal a Sharpening Focus on Epigenetics and Severe Disease
Sjögren’s syndrome remains difficult to define at the bedside because dry eyes and dry mouth are only the most visible parts of a broader systemic inflammatory disorder. The deeper problem is diagnostic: clinicians still lack a non-invasive, specific biomarker that can cleanly separate disease subtypes, gauge prognosis, and flag organ-threatening complications early enough to matter.
A data-driven bibliometric analysis of 1,118 articles published over the past two decades now offers a map of where the field has been, and where it is heading. Rather than testing a new treatment or diagnostic assay, the study traces the structure of the literature itself, using Web of Science Core Collection records and network tools including VOSviewer, CiteSpace, and Bibliometrix to chart countries, institutions, journals, authors, citations, and recurring keywords.
China and the United States Dominated Output, While Paris Anchored Institutional Productivity
The publication pattern was uneven but unmistakable. China and the United States led the field in both volume and citation frequency, a combination that usually signals not only productivity but also a high degree of influence on subsequent research directions. At the institutional level, Assistance Publique-Hôpitaux de Paris emerged as the most prolific center, reflecting the long-standing role of European rheumatology networks in Sjögren’s syndrome research.
The author-level picture was similarly concentrated. Xavier Mariette stood out across publication volume, h-index, and total citations, placing him at the center of the biomarker literature’s intellectual core. In a field shaped by heterogeneous clinical expression, that kind of consistent output matters because it often drives cohort design, biomarker priorities, and the language used to frame disease subsets across studies.
One journal also rose above the rest. Annals of the Rheumatic Diseases emerged as the most influential journal in the network, a result that fits the journal’s role as a major venue for translational rheumatology and clinical immunology.
Biomarkers Have Moved Beyond Single Molecules Toward Molecular Pattern Recognition
The keyword analysis shows a field that has shifted away from narrow biomarker hunting and toward broader molecular architecture. Over time, the literature expanded toward “DNA methylation,” “genes,” “interstitial lung disease,” and “data-driven” approaches, a sequence that captures the changing logic of research in Sjögren’s syndrome.
That progression is clinically meaningful. DNA methylation points to epigenetic regulation rather than isolated protein measurements, suggesting that disease activity may be shaped by durable changes in gene expression programs inside immune and glandular tissue. Gene-focused work expands the search into inherited susceptibility and transcriptional control. Data-driven approaches, meanwhile, reflect the growing use of integrative analytics to identify patterns that traditional single-marker studies can miss.
The appearance of interstitial lung disease as a recurring theme is especially important. Pulmonary involvement marks a more severe phenotype in Sjögren’s syndrome, and its emergence in the biomarker literature indicates that investigators are no longer interested only in classification or sicca symptoms. The field is moving toward markers that may distinguish patients at risk for systemic extension, a shift with obvious implications for surveillance and stratification.
Biologically, that makes sense. Sjögren’s syndrome is not a single-organ dryness syndrome; it is an immune-mediated disorder with B-cell activation, inflammatory signaling, and tissue injury that can extend beyond the exocrine glands. Biomarkers that capture epigenetic dysregulation or multiorgan involvement are more likely to reflect the true biology of the disease than those built around one-dimensional glandular readouts.
Publication Fluctuations Point to a Maturing Field Rather Than Linear Expansion
Publication trends did not rise in a straight line. They fluctuated over the years, which often happens when a field passes from early exploratory work into a more mature phase where incremental gains replace rapid growth. In practical terms, that pattern suggests the literature has already absorbed many of the obvious targets and is now searching for more discriminating markers tied to phenotype, prognosis, and comorbidity burden.
This is where bibliometrics becomes more than an academic exercise. A field with scattered topics, repeated keyword clusters, and a small set of highly influential authors usually signals a research area that has stabilized around a few dominant questions. Here, those questions appear to center on immune regulation, molecular signatures, and severe organ involvement rather than on diagnosis alone.
The study also reinforces a central clinical frustration: the shortage of accessible, reliable biomarkers has limited progress in early recognition and prognostic assessment. Without a robust non-invasive marker, clinicians still lean heavily on symptoms, serology, glandular testing, and clinical judgment, all of which can leave uncertainty in patients whose disease does not follow a textbook pattern.
What the Atlas Suggests for the Next Phase of Sjögren’s Syndrome Research
The strongest signal from this analysis is directional rather than definitive. Future work in Sjögren’s syndrome biomarkers is likely to cluster around epigenetics, multi-omics integration, and markers linked to systemic complications rather than around isolated candidate molecules. The keyword rise in “data-driven” studies points toward a more computational era, where transcriptomic, epigenetic, and clinical data are layered together to define clinically meaningful subgroups.
That evolution could improve patient care if it produces markers that predict who will develop pulmonary disease, who carries a higher inflammatory burden, and who may need closer monitoring or earlier intervention. It could also sharpen clinical trial design by enriching cohorts with biologically coherent subtypes instead of broad, mixed populations.
Still, bibliometric maps cannot validate a biomarker. They can only show where investigators have concentrated their effort and which ideas are gathering momentum. The study does not establish diagnostic accuracy, prognostic value, or clinical utility for any specific molecule.
The most actionable message is narrower: Sjögren’s syndrome biomarker science is moving from descriptive cataloging toward mechanism-based stratification, and the next major advances are likely to come from epigenetic and multi-omics work tied to severe systemic phenotypes rather than from simple one-marker assays.